Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Goblet pancreatic results -> ONCY moves to registration

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 08, 2022 11:18am

206 Views

Post# 35082083

RE:RE:Goblet pancreatic results -> ONCY moves to registration

If anyone is paying attention .. Pfizer has been messaging on their relentless pursuit of breakthrough science and revolutionary medicines .. which ONCY's platform technology in pelareorep represents.

https://www.pfizer.com/

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property